

Omics-based Bioactives and Drug Discovery

Albert Remus R. Rosana, Mohamed Seghir Daas, Jeella Z. Acedo, Farida Nateche,

Salima Kebbouche-Gana, John C. Vederas and Rebecca J. Case



Background



- **Peptide therapeutics are** emerging novel antimicrobials with great medical and biotech potential.
- **Bacillus** species have several predicted bioactive secondary metabolites encoded in their genome.

Oil and petroleum-





õõ

S

C

Ζ

L

A. Phenotype, genomics, and bio-actives mining









RNA Metabolism (157)

DNA Metabolism (109)

📔 Stress Response (109)

Respiration (74)

Nitrogen Metabolism (29)

Sulfur Metabolism (40)

Phosphorus Metabolism (31)

Protein Metabolism (176)

Motility and Chemotaxis (87)

Regulation and Cell signaling (65) Secondary Metabolism (6)

Dormancy and Sporulation (116)

Nucleosides and Nucleotides (121)

Fatty Acids, Lipids, and Isoprenoids (143)

Metabolism of Aromatic Compounds (11)

Amino Acids and Derivatives (436)

Fig 3. Phenotypic characteristics of biosurfactant-producing *Bacillus* spp. isolated from oil-mining sites in Algeria. Peritrichously flagellated cell (A), subcentral endospore (B), parasporal bodies (C), and "lipid vesicles" (D).

Amino Acids and

Derivatives



contaminated sites may harbor microbes (e.g. Bacillus) that has unique bioactive pathways and products.

Objectives

Fig2. B. paralicheniformis, biosurfactant producer isolated from Algeria

- 1. To sequence the genome of bioactive *Bacillus* spp. isolated from oil-contaminated sites for secondary metabolite (bioactives) mining.
- 2. To characterize the bioactives (lipopeptides) isolated from biotechnologically promising Bacillus spp.

A. Genomics & Bio-Informatics Tools



Fig 4. Circular genome of 4 **Bacillus** spp. Blast atlas analysis using *B. subtilis* as reference genome.

Carbohydrates (406) Fig 5. Proportion of genes in *B. thuringiensis* **DNG9** associated with the 27 general COG functional categories generated using RAST analysis pipeline.



Fig 6. Hybrid NRPS-PKS fengycin biosynthetic cluster. Gene cluster predicted in the genome of *B. amyloliquefaciens* F11 using antiSMASH. Fengycin, a strong antifungal and antibacterial lipopeptide shown with a cyclic peptide and a short fatty acid moiety (insert)



B. Lipopeptides, antibiotics and novel drugs



Fig 7. HPLC spectra of *Bacillus* sp. F11 cell lysate active fraction against Gram +/- bacteria.



ш





L. lactis

C. divergens

201

Fig 8. Spot-on-lawn assay. Active cell fraction (HPLC) where tested against the indicator test bacterium. Positive zone of inhibition shown with clearing.

- *Bacillus* spp. may contain >20 secondary metabolites such as the lipopeptide-FENGYCIN
- Genome mining revealed an bioactives from arsenal of Bacillus from isolated spp. petroleum-contaminated sites.



Fig 9. Predicted protein structure of the peptide moiety of fengycin

Combining OMICS approaches gene cluster bioactive for mining and secondary metabolite discovery could help accelerate microbial drug discovery.

□ To elucidate the structure of fengycin (nuclear magnetic resonance)







Ζ

U



